Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

Categories Prevention, Screening

41 through 50 of 100

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: Women considering breastfeeding who have inherited BRCA mutations.

Data from a large-scale study suggests that breastfeeding may protect against ovarian cancer in women with inherited mutations in BRCA1 or BRCA2. (1/28/21)

Este artículo está disponible en español.

Read More

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Update : FDA approves new imaging drug for detecting spread of prostate cancer

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Men with prostate cancer

On December 1, 2020 the FDA approved a new type of imaging technology to confirm the spread of newly diagnosed prostate cancer that is suspected to be metastatic. The approval also includes use for confirming suspected recurrence in men who have rising PSA after treatment. The approval is based on two clinical trials that showed this new technique to be safe and consistent in accurately detecting cancer that has spread beyond the prostate gland. (1/7/21)

THIS INFORMATION HAS BEEN UPDATED on 5/10/2022:  On March 23, 2022 the U.S. Food and Drug Administration (FDA) approved a new drug called Pluvicto to treat patients with metastatic castration-resistant prostate cancer. ON the same day, the FDA also approved a new imaging drug called Locametz (a brand of Gallium 68 PSMA-11) for identification of those patients who would benefit from treatment with Pluvicto. Read about the FDA approval of Pluvicto and Locametz here.

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Women support delayed removal of ovaries

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: Women at high risk of ovarian cancer who are considering undergoing risk-reducing surgery.

Risk-reducing early removal of fallopian tubes followed by removal of ovaries at a later date was acceptable to women at high risk of ovarian cancer due to an inherited mutation in a recent study. This was especially true for women worried about sexual dysfunction associated with surgical menopause. (12/24/20)

Read More

Relevance: Medium

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Study : Inherited gene mutations found in pancreatic cancer families in Spain

Relevance: Medium

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with pancreatic cancer and a family history of pancreatic or other cancers

This study looked for inherited mutations in genes known to be linked to hereditary pancreatic cancer. The results provide additional evidence that most hereditary pancreatic cancer is due to inherited mutations in genes that were previously associated with other forms of cancer. (10/29/20)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Young women with, or at high risk for an inherited BRCA mutation

Inherited mutations in the BRCA1 and BRCA2 genes are linked to a high lifetime risk of breast and other cancers. This study shows that women who know that they have a BRCA mutation before they are diagnosed with breast cancer have improved outcomes including diagnosis at earlier stages and improved overall survival. (10/26/20)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : New imaging technology shows promise in detecting of spread of prostate cancer

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: Men with high-risk prostate cancer

A new imaging technique is currently being tested to see if it can detect the spread of prostate cancer sooner than standard imaging. Two clinical trials show that the new technique can detect the spread of prostate cancer in men who are newly diagnosed and in men whose cancer returns after treatment. (10/16/20)

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

Study : What is the risk for a new breast cancer diagnosis in the other breast for women with a BRCA1, BRCA2 or TP53 mutation?

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

Most relevant for: Women diagnosed with breast cancer who have a mutation in BRCA1, BRCA2 or TP53

For women who have been diagnosed with breast cancer, knowing their risk of breast cancer in the other (contralateral) breast can help them make decisions about surgery and screening. This study shows that women with an inherited mutation in BRCA1, BRCA2 or TP53 have an increased risk for contralateral breast cancer. This risk is highest in women with a TP53 mutation. (6/6/20)

Read More

Relevance: High

Strength of Science: Medium-High

View Related Clinical Trials

Study : Racial and ethnic differences in genetic testing among young breast cancer survivors

Relevance: High

Strength of Science: Medium-High

View Related Clinical Trials

Most relevant for: Women diagnosed with breast cancer at age 50 or younger

Genetic testing is recommended for most women who are diagnosed with breast cancer at age 50 or younger.  In this study of young women with breast cancer, while the rates of genetic testing  did not differ, the rates of women testing positive for an inherited mutation associated with breast cancer did vary between racial and ethnic groups. (2/27/20)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Cancer risk associated with inherited mutations in Lynch syndrome genes

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with Lynch syndrome mutations

Lynch syndrome is the most common inherited cause of cancer affecting about 1 in 300 people. People with Lynch syndrome have an increased risk of colorectal endometrial and other cancers. A large study followed people with mutations in the Lynch syndrome genes MLH1, MSH2, MSH6 and PMS2 to determine the risk of other types of cancer. (2/21/20)

Read More

Relevance: Medium-High

Strength of Science: Medium-Low

Study : Do hair dyes or straighteners increase breast cancer risk?

Relevance: Medium-High

Strength of Science: Medium-Low

Most relevant for: Young women who use hair dye or straighteners

Many women use products to color or straighten their hair. A large U.S. study linked the use of permanent hair dye and straighteners to increased breast cancer risk, particularly among black women. This XRAY reviews the limitations of this study and highlights the need for additional research before accepting these conclusions. (1/29/20)

Read More